Macular degeneration

Ophthotech Fovista AMD Phase 3 trials results come up short

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Eylea® (aflibercept) or Avastin® (bevacizumab) anti-VEGF therapy compared to Eylea or Avastin monotherapy for the treatment of

READ MORE…

(c) Ophthotech

Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista ® in Wet AMD

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating superiority of Fovista (pegpleranib) anti-PDGF therapy in combination with Lucentis (ranibizumab) anti-VEGF therapy compared to Lucentis monotherapy for the treatment of wet age-related macular degeneration

READ MORE…